Abstract:【Abstract】Objective To investigate the effects of conditioning with ChiCGB (chidamide+cladribine+gemcitabine+busulfan) in patients with nonHodgkin's lymphoma (NHL) before autologous hematopoietic stem cell transplantation. Methods The relevant data of 66 patients with NHL admitted to the hospital between March 2015 and July 2019 were retrospectively analyzed. All patients were treated with autologous hematopoietic stem cell transplantation and conditioning with ChiCGB regimen before transplantation. The collection of autologous hematopoietic stem cells, hematopoietic reconstruction after transplantation, regimenrelated toxicity, curative effect and survival were analyzed. Results The medians of collected mononuclear cells and CD34+ cells were 1136×108/kg and 1368×106/kg, respectively. 66 patients successfully completed hematopoietic reconstruction, and the average granulocyte implantation time and average platelet implantation time was (1032±314) d and (1228±706) d, respectively. The incidence of infection during transplantation was 5606%, and the incidence rates of grade 2 or higher grade of bleeding, mucositis, liver injury, diarrhea, fever, nausea and vomiting during transplantation were 758%, 2576%, 2576%, 5606%, 3636% and 6667%, respectively. 46 and 17 patients achieved complete remission and partial remission in 3 months, respectively, and the overall response rate after transplantation was 9545%. The 1year OS rate and PFS rate were 8485% and 7121%. The 3year OS rate and PFS rate were 7273% and 6061%, respectively. Univariate and COX regression analyses showed that disease stage and refractory or recurrent disease were independent risk factors affecting patients’ 3year OS rate (P<005). Disease stage was an independent risk factor for the 3year PFS rate (P<005).Conclusion There is no intolerable toxicity caused by conditioning with ChiCGB regimen in patients with NHL before autologous hematopoietic stem cell transplantation. Besides, the prognosis is good. It is a safe and effective conditioning regimen for such patients.